Table 1.
Population samples and microarray experiments
| Population sample | Fluconazole MIC, μg/ml | Fitness with drug* | Fitness without drug | Microarray (no. ORFs) | Replicate hybridizations‡ |
|---|---|---|---|---|---|
| N4-330 | 0.25 | 0.10 ± 0.27 | 0.31 ± 0.12† | 4,651 | 6 |
| 3,609 | 4 | ||||
| D8-330 | 4.0 | 1.72 ± 0.27† | 0.46 ± 0.06† | 4,651 | 6 |
| 3,609 | 4 | ||||
| D9-165 | 4.0 | — | — | 5,669 | 6 |
| D9-330 | 64.0 | 0.62 ± 0.21† | −0.25 ± 0.11 | 4,651 | 6 |
| 3,609 | 4 | ||||
| D11-330 | 64.0 | −0.21 ± 0.14 | −0.27 ± 0.09 | 5,669 | 6 |
| D12-165 | 4.0 | — | — | 5,669 | 6 |
| D12-260 | 64.0 | −0.11 ± 0.07 | −0.35 ± 0.01† | 4,651 | 8 |
| 3,609 | 2 | ||||
| D12-330 | 4.0 | 0.38 ± 0.18 | −0.09 ± 0.12 | 5,669 | 6 |
In a previous study (11), fitness was measured relative to the genetically marked ancestor as the difference in the number of doublings of the two competitors (evolved population sample minus ancestor), standardized by the total number of doublings in the competition assay. Fitness measurements are the average from three replicates ± 95% confidence intervals. For competition experiments with the drug, the concentrations of fluconazole used were: 0.5 μg/ml for N4-330 and 128 μg/ml for the remaining population samples.
The difference in the number of doublings of the two competitors was significant (paired t test, P < 0.05).
The replicate hybridizations include an equal number of experiments with the paired samples reciprocally labeled. For each set of reciprocal hybridizations an independent RNA preparation was used, for both the evolved population sample and the ancestor.